Study guide
12.2 CoC Standard 6.5 Follow-Up Rates: Windows, Exclusions & Calculations
NCRA Oncology Data Specialist ODS-C
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: The ODS-C Exam, the Oncology Data Specialist Profession & Standard Setters
1.1 ODS Exam Structure, Timing, Scoring & 2026 Testing Windows 1.2 From CTR to ODS: The Credential, Eligibility Routes & the Registrar's Role 1.3 Standard-Setting Organizations & the Manuals They Publish
2 Chapter 2: Legal Framework, HIPAA & State Reporting Laws
2.1 HIPAA Privacy Rule & the Public Health Reporting Exception 2.2 HIPAA Security Rule, Safeguards & Breach Notification 2.3 State Mandatory Cancer Reporting Laws & Statutory Authority
3 Chapter 3: Confidentiality, Release of Information, Ethics & Credential Maintenance
3.1 Patient Confidentiality Protocols & Data Access Policies 3.2 Handling Subpoenas, Discovery & Registry Immunity Statutes 3.3 NCRA Code of Ethics & ODS Credential Maintenance
4 Chapter 4: Registry Organization, Staffing & Information Systems
4.1 Types of Cancer Registries, Their Functions & Registry Operating Protocols 4.2 Registry Staffing Formulas, Time Studies & Resource Allocation 4.3 Electronic Registry Systems, Security & Disaster Recovery Planning
5 Chapter 5: Cancer Committee, Cancer Conferences & Quality Improvement
5.1 The Cancer Committee: CoC Standards 2.1–2.4, the CLP & Annual Program Activities 5.2 Multidisciplinary Cancer Case Conferences (CoC Standard 2.5) 5.3 Quality Improvement Principles & CoC Chapter 7 (Standards 7.1–7.3)
6 Chapter 6: CoC Accreditation Standards, NCDB & Data Quality
6.1 CoC Accreditation: Standards Structure, Program Categories & Accreditation Awards 6.2 The National Cancer Database (NCDB), RCRS Submission & CoC Quality Measures 6.3 Quality Control Plans & Audit Techniques (CoC Standard 6.1)
7 Chapter 7: Surveillance Programs, NAACCR Standards, Epidemiology & Statistics
7.1 National Cancer Surveillance Programs: SEER & CDC NPCR 7.2 NAACCR Data Exchange Standards, XML Data Specifications & Registry Certification 7.3 Basic Cancer Epidemiology & Descriptive Statistics 7.4 Basic Statistics: Frequency Distributions, Central Tendency, Risk Ratios & Odds Ratios 7.5 Survival Analysis, Life Tables & Presentation of Registry Data
8 Chapter 8: Medical Terminology, Anatomy & Types of Cancer
8.1 Medical Terminology & Standard Abbreviations for Cancer Abstracting 8.2 Human Anatomy & Physiology for Registrars: Tissues, Organ Walls, Subsites & Lymphatic Drainage 8.3 Types & Characteristics of Cancer: Benign vs. Malignant, Tumor Families, Spread & Precursors
9 Chapter 9: Casefinding & Reportability
9.1 Principles of Casefinding & Facility Reference Dates 9.2 Casefinding Sources: Pathology, Cytology, Disease Index & Logs 9.3 Reportability: What CoC, SEER and NPCR Require, Including Non-Malignant CNS Tumors 9.4 Ambiguous Terminology: Reportable Terms, Cytology, Discrepancies & "References of Last Resort"
10 Chapter 10: Diagnostic Procedures, Pathology Reporting, Lab Methods & Prognostic Indicators
10.1 Diagnostic & Staging Procedures: Imaging, Endoscopy, Biopsy & How They Are Coded 10.2 Pathology Reporting, CAP Cancer Protocols & Electronic Pathology (CoC Standard 5.1) 10.3 Specialty Laboratory Testing Methods: IHC, FISH, PCR/RT-PCR, NGS, Flow Cytometry & Cytogenetics 10.4 Prognostic Indicators & Site-Specific Data Items (SSDIs): HPV, KRAS, HER2 and More
11 Chapter 11: Class of Case, Key Dates & Case Identifiers
11.1 Class of Case, Date of First Contact, Date of Diagnosis & Accession/Sequence Numbers 11.2 Analytic Classes of Case (00, 10–14, 20–22): Definitions & Decision Rules 11.3 Nonanalytic Classes of Case (30–49, 99) & Why Central Registries Need Them
12 Chapter 12: Follow-Up, Vital Status & Recurrence
12.1 Follow-Up Purpose, Active & Passive Methods, and Follow-Up Source Codes 12.2 CoC Standard 6.5 Follow-Up Rates: Windows, Exclusions & Calculations 12.3 Vital Status, Date of Last Contact, Cancer Status & Death Clearance 12.4 Recurrence: Type of First Recurrence [1880], Date of First Recurrence [1860] & Recurrence vs. New Primary
13 Chapter 13: Abstracting, ICD-O-3.2 Site & Histology Coding, and Grade
13.1 The Abstracting Process: Workflow, Source Documents, Timeliness & Text Documentation 13.2 ICD-O-3.2 Topography, Primary Site Rules & Laterality 13.3 ICD-O-3.2 Morphology: Histology, Behavior & the Solid Tumor Histology Rules 13.4 Grade: The Four Time-Specific Grade Items & Site-Specific Grade Tables
14 Chapter 14: Solid Tumor Rules & Hematopoietic Coding Rules
14.1 Solid Tumor Rules: Purpose, Site Groups, Navigation & Timing Principles 14.2 Solid Tumor Rules for Breast, Colon/Rectum & Lung: The Multiple Primary Rules in Order 14.3 Solid Tumor Rules for Head & Neck, Kidney, Urinary, CNS, Melanoma & Other Sites 14.4 Hematopoietic & Lymphoid Neoplasms: Heme Manual, Heme DB, Multiple Primary & Primary Site Rules
15 Chapter 15: Staging: AJCC TNM (8th Edition & Version 9 Lung) and Summary Stage 2018
15.1 AJCC TNM Principles: Categories, Prefixes, Suffixes, General Rules & Registry Items 15.2 AJCC Time Frames: Clinical, Pathological, Post-Therapy (yc, yp), Recurrence & Autopsy 15.3 Breast Staging (AJCC 8th Edition, Part XI): T, N, M, Anatomic & Prognostic Stage Groups 15.4 Lung Staging (AJCC Version 9, 2025+): T, N2a/N2b, M1c1/M1c2 & New Stage Groups 15.5 Male Genital & Urinary Tract Staging (AJCC 8th Parts XIII–XIV): Prostate, Testis, Kidney, Bladder, Renal Pelvis & Ureter 15.6 SEER Summary Stage 2018: Codes, Timing, General Rules & Site Examples
16 Chapter 16: First-Course Treatment Coding (STORE 2025) & EDITS
16.1 Treatment Types, First Course of Treatment & Evidence-Based Guidelines (NCCN) 16.2 Surgery Coding: Rx Summ–Surg 2023 [1291], Lymph Node Surgery [1292], Other Site [1294], Margins & Reason for No Surgery 16.3 Radiation, Systemic, Transplant, Other & Palliative Treatment Coding (STORE 2025) 16.4 NAACCR EDITS, Over-ride Flags & Data Validation
12.2 CoC Standard 6.5 Follow-Up Rates: Windows, Exclusions & Calculations
Key Takeaways Explain This Topic AI
Standard 6.5 requires an 80% follow-up rate for eligible analytic cases from the most current year of completed cases through 15 years before, or the program's first accreditation date if that is shorter.
It also requires a 90% follow-up rate from the most current year of completed cases through five years before, or the first accreditation date if that is shorter.
"Most current year of completed cases" means cases diagnosed three years before the current calendar year, so in 2026 the 80% window is 2009–2023 and the 90% window is 2019–2023.
Excluded from follow-up are residents of foreign countries, cases reportable by agreement, patients over 100 years old with no contact for more than 12 months, and Class of Case 00 cases.
Programs having their initial accreditation site visit are exempt from Standard 6.5, and the cancer committee monitors unknown values for recurrence date, recurrence type and cancer status.
Last updated: September 2026
The standard, word for word
The 2020 Optimal Resources for Cancer Care standards (updated through October 2025) place follow-up in Chapter 6, Data Surveillance and Systems, as Standard 6.5: Follow-Up of Patients . The measure of compliance has two parts:
An 80 percent follow-up rate is maintained for all eligible analytic cases from the most current year of completed cases through 15 years before , or the program's first accreditation date, whichever is shorter.
A 90 percent follow-up rate is maintained for all analytic cases diagnosed from the most current year of completed cases through five years before , or the program's first accreditation date, whichever is shorter.
At the site visit, the reviewer looks at the current follow-up report . Programs undergoing their initial accreditation site visit are exempt from Standard 6.5.
Finding the windows
CoC defines the "most current year of completed cases" as cases diagnosed three years before the current calendar year . The standard's own example: in calendar year 2022 , the long-term (80%) window is cases diagnosed 2005–2019 , and the short-term (90%) window is 2015–2019 . Both windows count the ending year, so "15 years" means 15 diagnosis years in total and "five years" means five.
- Current calendar year Most current completed year 80% window (15 years) 90% window (5 years)
- 2022 (CoC example) 2019 2005–2019 2015–2019
- 2025 2022 2008–2022 2018–2022
- 2026 2023 2009–2023 2019–2023
- 2027 2024 2010–2024 2020–2024
Shorter window rule: if the program was first accredited in, say, 2016, the 80% window in 2026 runs only from 2016 to 2023, because the first accreditation date gives a shorter window than 15 years.
Who is excluded
Standard 6.5 says all reportable cases are followed except :
Residents of foreign countries.
Cases reportable by agreement , such as tumor types that the cancer committee or state asks to be collected but CoC does not require.
Patients whose age exceeds 100 years and who have had no contact for more than 12 months .
Analytic cases with Class of Case 00.
Nonanalytic cases (Class of Case 30–99) are not in the denominator at all, because the standard applies to analytic cases.
Calculating a follow-up rate
A follow-up rate compares cases with successful follow-up to all eligible cases in the window:
Follow-up rate = eligible cases with successful follow-up all eligible analytic cases in the window × 100 \text{Follow-up rate} = \frac{\text{eligible cases with successful follow-up}}{\text{all eligible analytic cases in the window}} \times 100 Follow-up rate = all eligible analytic cases in the window eligible cases with successful follow-up × 100
Successful follow-up includes patients known to be dead , because the death date and vital status are final, and living patients whose information is current .
Current: the 2020 standard does not give a day count. Registry software follow-up reports commonly use the convention from earlier CoC standards and treat a living patient as current when the Date of Last Contact is within 15 months of the report date. That allows for an annual cycle plus processing time. Check your software's setting. Patients not current are lost to follow-up in the calculation.
Always remove exempt cases from both the numerator and the denominator.
Worked example (calendar year 2026)
The 90% window is 2019–2023.
- Item Count
- Analytic cases diagnosed 2019–2023 2,480
- Minus Class of Case 00 −160
- Minus foreign residents −12
- Minus reportable-by-agreement cases −48
- Eligible cases 2,260
- Known dead 610
- Alive, last contact within 15 months 1,440
- Successfully followed 2,050
Follow-up rate = 2,050 ÷ 2,260 = 90.7% , which meets the 90% requirement. If 30 more patients became lost to follow-up (2,020 ÷ 2,260 = 89.4%), the program would fall short.
Monitoring unknown values
Standard 6.5 also says the cancer committee monitors the use of unknown values to ensure complete data reporting. This matters most for Date of First Recurrence , Type of First Recurrence and Cancer Status . A registry that codes "99, unknown if recurred" for many patients has technically been followed but provides little outcome value. The standard also expects every CoC program to provide treatment or follow-up information and assistance to referring cancer programs .
Strategies to stay above the thresholds
Work the 5-year window first , because the 90% threshold is stricter and recent patients are easier to reach.
Run passive matches before letters : facility encounters, EHR portals, state central registry updates and death-index linkage often make many cases current without any mailing.
Use the right contact for each patient : the managing oncologist for recent cases, and the primary care physician or the patient for long-term survivors.
Track lost cases by diagnosis year and investigate spikes, which often come from registry conversions or staff turnover.
Report the rates to the cancer committee with an action plan when a rate is near the threshold.
Common exam traps
Standard 6.5 is the follow-up standard; there is no separate "Standard 5.3" follow-up rule in the 2020 standards.
The windows start at the most current completed year , which is three years before the current year, not the current year.
Dead patients count as successfully followed .
Class of Case 00 patients are analytic but are excluded from follow-up.